FOLH1 and prostate cancer: In another approach, Saharkhiz, S. et al and researchers utilized modified MSNs, specifically by coating their surfaces with a thermo-responsive cationic lipid functionalized with an anti-PSMA aptamer, to facilitate selective administration of paclitaxel (PTX) and CdSe/ZnS quantum dots (QDs) to prostate cancer cells that express PSMA.